Lv4
500 积分 2025-06-02 加入
Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial
1天前
已完结
Predictors of survival in patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib
2天前
求助中
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
2天前
已完结
Predictors of survival in patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib
11天前
已关闭
Predictors of survival in patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib
11天前
已关闭
Postprogression survival of patients with advanced hepatocellular carcinoma: Rationale for second-line trial design
21天前
已完结
Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial
21天前
已完结
Nivolumab and sorafenib in hepatocellular carcinoma: lessons from the CheckMate 459 study
21天前
已完结
More than the sum: How vascular endothelial growth factor inhibition unlocks the full potential of immune checkpoint blockade
22天前
已完结
Migratory Properties of Naive, Effector, and Memory Cd8+ T Cells
1个月前
已完结
皖公网安备34019202002308
